Changchun BCHT Biotechnology Co.

Shanghai Stock Exchange 688276.SS

Changchun BCHT Biotechnology Co. Free Cash Flow Yield on January 27, 2025: -3.09%

Changchun BCHT Biotechnology Co. Free Cash Flow Yield is -3.09% on January 27, 2025, a -132.13% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Changchun BCHT Biotechnology Co. 52-week high Free Cash Flow Yield is -1.24% on February 29, 2024, which is 60.03% above the current Free Cash Flow Yield.
Changchun BCHT Biotechnology Co. 52-week low Free Cash Flow Yield is -3.15% on September 18, 2024, which is -1.84% below the current Free Cash Flow Yield.
Changchun BCHT Biotechnology Co. average Free Cash Flow Yield for the last 52 weeks is -2.22%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Shanghai Stock Exchange: 688276.SS

Changchun BCHT Biotechnology Co.

CEO	Mr. Wei Kong
IPO Date	June 25, 2021
Location	China
Headquarters	1260 Huoju Road
Employees	1,241
Sector	Healthcare
Industries Vaccines Biotechnology Pharmaceuticals

Description

Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally. Its products include live herpes zoster vaccine; live varicella vaccine; live, nasal, and freeze-dried influenza vaccine; and Rabies vaccine (vero cell) for humans. The company was founded in 2004 and is based in Changchun, China.

Key trends

Past 5 years